A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

202

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

July 31, 2029

Conditions

Classic Hodgkin Lymphoma

Interventions

BIOLOGICAL

Tislelizumab

IV infusion

BIOLOGICAL

IMM01

2.0mg/kg, IV infusion

DRUG

Bendamustine

IV infusion

DRUG

Gemcitabine

IV infusion

All Listed Sponsors

lead

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

OTHER